ArticleCureus2026
Atopic Dermatitis During Ustekinumab Therapy in a Patient With Ulcerative Colitis: A Case Report and Review of Targeted Therapies in Coexisting Diseases.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atopic dermatitis (AD) and ulcerative colitis (UC) are immune-mediated inflammatory diseases that may coexist, creating therapeutic challenges during biologic treatment. Here, we report a patient with long-standing AD and UC who was receiving ustekinumab therapy for UC and subsequently developed worsening eczema. In such cases, distinguishing an AD flare from a drug-induced eruption or secondary infection is a key clinical challenge because this distinction directly influences decisions regarding continuation or discontinuation of biologic therapy. Clinicopathologic evaluation supported the diagnosis of an AD flare rather than a drug-induced reaction. Temporary discontinuation followed by resumption of ustekinumab did not result in recurrence of cutaneous lesions, and the patient's UC remained stable. In addition, we conducted a focused review of previously reported cases of patients with concurrent AD and UC treated with biologics or Janus kinase (JAK) inhibitors and summarized their clinical characteristics and outcomes. This report highlights clinical considerations when selecting biologic or targeted therapies in patients with coexisting AD and UC and underscores the importance of careful clinicopathologic assessment of cutaneous eruptions during biologic therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.